Could a lower dose of a standard pneumonia drug be safer and just as effective?
NCT ID NCT04851015
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study is for people with weakened immune systems who have a serious lung infection called PCP. The standard treatment often causes harsh side effects. Researchers want to see if a lower dose of the drug works just as well but with fewer side effects. About 416 adults will take part, and the study compares the lower dose to the standard dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITINGMontreal, Quebec, H4A3J1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.